Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Groups, Phase 1 Clinical Study Comparing the Pharmacokinetic, Safety and Immunogenicity of Adalimumab in Healthy Subjects

NCT06291948 is registered in ClinicalTrials.gov with Laboratorios Richmond S.A.C.I.F. as lead sponsor.

NCT NCT06291948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Groups, Phase 1 Clinical Study Comparing the Pharmacokinetic, Safety and Immunogenicity of Adalimumab in Healthy Subjects
Lead sponsor
Laboratorios Richmond S.A.C.I.F.
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2022
Completion date
October 20, 2023
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics, safety issues